Low risk of pancreatitis in HIV-infected patients on hydroxyurea plus didanosine.
作者信息
Barreiro P, Soriano V, Valencia E, Díaz B, González-Lahoz J
出版信息
AIDS. 2001 Dec 7;15(18):2469-70. doi: 10.1097/00002030-200112070-00024.
Abstract
摘要
相似文献
1
Low risk of pancreatitis in HIV-infected patients on hydroxyurea plus didanosine.
AIDS. 2001 Dec 7;15(18):2469-70. doi: 10.1097/00002030-200112070-00024.
2
Incidence of pancreatitis in HIV-infected patients receiving nucleoside reverse transcriptase inhibitor drugs.
AIDS. 2001 Mar 30;15(5):617-20. doi: 10.1097/00002030-200103300-00011.
3
Didanosine plus stavudine with or without hydroxyurea in HIV-1-infected patients: 1 year follow-up. Swiss HIV Cohort Study.
Antivir Ther. 1998;3 Suppl 4:65-7.
4
Activity, safety, and immunological effects of hydroxyurea added to didanosine in antiretroviral-naive and experienced HIV type 1-infected subjects: a randomized, placebo-controlled trial, ACTG 307.
AIDS Res Hum Retroviruses. 2004 Sep;20(9):916-26. doi: 10.1089/aid.2004.20.916.
5
Incidence of neuropathy in HIV-infected patients on monotherapy versus those on combination therapy with didanosine, stavudine and hydroxyurea.
AIDS. 2000 Feb 18;14(3):273-8. doi: 10.1097/00002030-200002180-00009.
6
Didanosine once daily: potential for expanded use.
AIDS. 2000 Nov 10;14(16):2421-8. doi: 10.1097/00002030-200011100-00002.
7
Heart attack risk with abacavir and didanosine.
AIDS Patient Care STDS. 2008 Apr;22(4):346-7.
8
[Didanosine--stability as backbone drug].
MMW Fortschr Med. 2005 Apr 25;147 Spec No 1:83-4.
9
Therapeutic advantage of hydroxyurea and didanosine combination therapy in patients previously treated with zidovudine.
AIDS. 1998 Jun 18;12(9):1113-4.
10
Incidence of pancreatitis in HIV-infected patients: comment on findings in EuroSIDA cohort.
AIDS. 2008 Jan 2;22(1):145-7. doi: 10.1097/QAD.0b013e3282f030a9.
引用本文的文献
1
Hydroxyurea-Induced Acute Pancreatitis.
Cureus. 2022 Jun 20;14(6):e26132. doi: 10.7759/cureus.26132. eCollection 2022 Jun.
Zotero 插件